Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above 200-Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $34.94 and traded as high as $43.50. Global X Genomics & Biotechnology ETF shares last traded at $43.38, with a volume of 4,967 shares changing hands.

Global X Genomics & Biotechnology ETF Price Performance

The stock has a fifty day moving average price of $38.82 and a 200-day moving average price of $34.94. The company has a market cap of $52.92 million, a PE ratio of -18.54 and a beta of 1.03.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently modified their holdings of the stock. Creative Financial Designs Inc. ADV acquired a new position in shares of Global X Genomics & Biotechnology ETF in the first quarter worth $95,000. Halbert Hargrove Global Advisors LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 182.4% in the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock worth $115,000 after acquiring an additional 8,839 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 18.5% in the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock worth $125,000 after acquiring an additional 2,329 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after acquiring an additional 2,184 shares during the last quarter. Finally, Oxinas Partners Wealth Management LLC increased its position in Global X Genomics & Biotechnology ETF by 12.1% during the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after buying an additional 1,751 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.